Healthy Returns: Here are the drugmakers with new U.S. investments as Trump's pharma tariffs loom
1. Pharmaceutical investments surge in the U.S. amid tariff threats. 2. Major drugmakers announce billions in U.S. manufacturing commitments. 3. Rising production costs could lead to higher drug prices. 4. Pfizer cites tariff uncertainty as a barrier to further investments. 5. Reshoring manufacturing aims to stabilize the drug supply chain.